Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) Fair Value & Analysis
Healthcare · CN · Market cap 42.9B CNY (≈ $6.4B) · ISIN CNE1000062X2
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd really worth?
A strong business, trading 46% below our fair value of ¥78.27.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 22 days ago
Share price −1.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (82/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The model range is unusually wide (¥40.49 to ¥142.69). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥8.25 – ¥62.92 · fair‑value band ¥40.49 – ¥142.69 · the ¥42.16 price screens below the ¥78.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) currently trades at ¥42.16, while our model-based Fair Value estimate is ¥78.27, implying the stock looks roughly 46.1% undervalued today. The Quality Score stands at 82/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ¥109.76 per share, and 17 of the 25 models we run sit above the ¥42.16 price. Bear case: the Multiples group reads lowest at ¥29.42, and 8 of the 25 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Sunshine Guojian Pharmaceutical Shanghai Co Ltd generated revenue of 4.3B CNY at a net margin of 68.9%. Revenue grew 38.6% year over year. It earns a return on equity of 41.8%. The balance sheet holds a net cash position of 409M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥40.49 (bear case) to ¥142.69 (bull case); at ¥42.16, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at 86%, 688336 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥2.92 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 25 models by family
Widest divergence: Growth Earnings (¥109.76) versus Dividend Discount (¥1.37). Highest evidence: FCF DCF (73).
Notify me when 688336 reaches fair value
Put 688336 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 80 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs.
Full company description
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sunshine Guojian Pharmaceutical Shanghai Co Ltd reported revenue of 4.2B CNY in FY2025 versus 929M CNY in FY2021, a compound +45.8%/yr. Reported net income was 2.9B CNY in FY2025, compounding +257.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
of which total revenue +10.5 % · buybacks/dilution −2.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch 688336: get an alert when its fair value changes →
Peer Group
Biotechnology · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
Compare Sunshine Guojian Pharmaceutical Shanghai Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) overvalued or undervalued?
What is the fair value of 688336?
What is the quality score of 688336?
What is the revenue of Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336)?
What is the net profit margin of 688336?
Does Sunshine Guojian Pharmaceutical Shanghai Co Ltd pay a dividend?
Watch Sunshine Guojian Pharmaceutical Shanghai Co Ltd in the live analysis
One click puts Sunshine Guojian Pharmaceutical Shanghai Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.